ClinicalTrials.gg
SuspendedNCT02728284Updated Oct 29, 2026

Evaluation of Cardiac Function With Cardio-respiratory Synchronized MRI

An interventional study of cardiovascular MRI (CMR) and Conventional Cardiologic Evaluation in Heart Disease, sponsored by NYU Langone Health. Suspended at 1 site in United States. Open to participants aged 7 Years to 95 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by NYU Langone Health · Not applicable, Interventional, and Diagnostic

How we know

Why this study was suspended
COVID-19
Updated Oct 29, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
7 Years to 95 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 646 studies in Heart Diseases with a site in United States — 92 open to participants now, 131 under way, 5 of them phase 3. Heart Diseases · United States.

Planned enrollment
265th of 430
100 · median 161
Started
2018
with 26 others
No phase
244 of 646
40 open now
Registered
385th of 646
by date

Among the 646 studies in Heart Diseases with a site in United States, this one is the 265th largest by planned enrollment of the 430 interventional ones that give a count, is one of 27 that started in 2018, is one of 244 with no phase, and was the 385th registered.

Heart Diseases

2,135 studies on the registry are indexed under Heart Diseases; 250 are open to participants now.

Browse Heart Diseases studies →

Open to participants now

92 of the 646 studies in Heart Diseases with a site in United States are open now. Recruiting first, the newest first:

87 more — sign in →

All 92 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 182 Heart Diseases studies recruiting now, 128 (70%) set no upper age limit and 22 (12%) stop at 75 or younger; 33 take children under 18; 41 take healthy volunteers.

This study: 7 Years to 95 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 646 studies in Heart Diseases with a site in United States, or all of them as a file.
02

Study summary

The purpose of this investigation is to evaluate newer methods of performing cardiovascular MRI (CMR) that will provide new kinds of information related to the interplay between the cardiac and the respiratory cycles, such as the interaction between the left ventricle and the right ventricle during respiration . The primary statistical objective is to provide preliminary indications of the relative utility of the investigational imaging software in terms of image quality and suitability for routine clinical use. Image quality will be expressed in terms of signal-to-noise ratios (SNR), contrast-to-noise ratios (CNR) and subjective Likert-type qualitative assessments independently provided by each of multiple blinded readers for each image. Suitability for routine use will be assessed in terms of imaging time and a binary indicator of whether, in the opinion of the investigator, adverse procedural complications (not expected) were encountered during a given imaging session.

03

Conditions studied

  • Heart Disease

Browse trials for

Keywords

  • Magnetic Resonance Imaging (MRI)
04

Who can participate

Ages eligible
7 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects will be selected as they are scheduled for clinical MR examinations.
  • Subjects will be selected on the basis of their willingness and ability to participate, on their comprehension of the document, on their likelihood of completing the study, and on the clinical appropriateness of the technique for a given patient.

Exclusion criteria

Exclusion Criteria:

  • electrical implants such as cardiac pacemakers or perfusion pumps
  • ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants
  • ferromagnetic objects such as jewelry or metal clips in clothing
  • pre-existing medical conditions including a likelihood of developing seizures or claustrophobic reactions, and any greater than normal potential for cardiac arrest.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Normal Cardiovascular System

    70 with a history of heart or lung disease

    Procedure: cardiovascular MRI (CMR)

  • Active comparator
    Abnormal Cardiovascular System

    30 without any history of heart or lung disease

    Procedure: Conventional Cardiologic Evaluation

Interventions

  • Procedurecardiovascular MRI (CMR)

    CMR is used to demonstrate cardiac abnormalities and assess cardiac function in many patients

  • ProcedureConventional Cardiologic Evaluation

    ECG (gating), and respiratory motion effects

06

What researchers measure

Primary outcomes

  1. Image Quality measured by resolution

    Time frame: 10 Minutes

  2. Image Quality measured by signal to noise

    Time frame: 10 Minutes

  3. Suitability for routine use measured by imaging time and ease of use

    Time frame: 10 Minutes

07

Study locations

1 site
  • New York University School of Medicine
    New York, New York 10016, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Mar 2018 (actual). Primary completion is estimated for Aug 2028, 125 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Aug 2027 → Aug 2028 and completion Aug 2027 → Aug 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2016
First posted
Apr 5, 2016
StartActual
Mar 29, 2018
Primary completionEst.
Aug 2028was Aug 2027
CompletionEst.
Aug 2028was Aug 2027
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 2027→Aug 2028
Oct 29, 2026
Study completion
Aug 2027→Aug 2028
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Primary completion Aug 2027→Aug 2028
    Study completion Aug 2027→Aug 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT02728284
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Apr 5, 2016
Start date
Mar 29, 2018
Primary completion
Aug 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Oct 29, 2026

Study contacts

Leon Axel
principal investigator · New York University Medical School

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion